About Qualigen Therapeutics Inc
Qualigen Therapeutics (NASDAQ:QLGN) focuses on the development and commercialization of novel therapeutic and diagnostic products. Based on its core expertise in precision medicine, the company is dedicated to advancing treatments in the fields of oncology, infectious diseases, and degenerative diseases. A key highlight in its pipeline is the STARS™ technology aimed at treating solid tumors, along with ongoing projects targeting leukemia and viral infections. Qualigen is committed to leveraging its research capabilities to deliver effective medical solutions and improve patient outcomes. The company's objectives revolve around developing high-impact therapies while expanding its market presence and building strategic partnerships in the biotech industry.
Snapshot
Operations
Produtos e/ou serviços de Qualigen Therapeutics Inc
- QLN-247 is a small molecule selective inhibitor of G4DNAs that offers potential treatment for cancers, addressing multiple tumor types by targeting their DNA replication mechanisms.
- QLN-248 aims to treat hypoxia-related comorbidities in solid tumors, potentially unlocking a pathway to tackle tumor environments resistant to traditional therapies.
- FastPack diagnostic platform provides rapid and accurate diagnostic testing across various medical conditions, crucial for timely decision-making in clinical settings.
- Q-NAT technology is used for ultra-sensitive detection and quantification of viral load and pathogens, offering significant improvements in molecular diagnostics.
- QLN-601 is a small molecule mIDH1 inhibitor intended for the treatment of solid tumors, potentially enhancing outcomes in cancers with IDH1 mutations.
- STARS (Supportive Therapeutics for Acute Radiation Syndrome) seeks to develop treatments mitigating the effects of radiation exposure, offering essential support for accidental or intentional radiation events.
equipe executiva do Qualigen Therapeutics Inc
- Mr. Kevin A. Richardson IICo-CEO, Chief Accounting Officer & Chairman of the Board
- Mr. Robert W. Campbell BecherPresident
- Mr. Michael S. PoirierChief Operating Officer
- Mr. Christopher L. LotzVP of Finance & Corporate Secretary
- Mr. Jiawei WangCo-Chief Executive Officer
- Mr. Koti MekaChief Financial Officer